Stock Screener App

Frei -

Installieren

90.44

3.69% 3.22

Arcellx Inc (ACLX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Arcellx Inc Aktie (ACLX) Neueste Nachrichten

RA CAPITAL MANAGEMENT, L.P. Increases Stake in Arcellx Inc - GuruFocus.com

(ACLX) Proactive Strategies - Stock Traders Daily

arcellx CFO Michelle Gilson sells $156,508 in shares By Investing.com - Investing.com Canada

arcellx CFO Michelle Gilson sells $156,508 in shares - Investing.com India

Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year? - MSN

First Turn Management LLC Makes New Investment in Arcellx, Inc. (NASDAQ:ACLX) - MarketBeat

Arcellx, Inc. (NASDAQ:ACLX) Position Reduced by Victory Capital Management Inc. - MarketBeat

First Week of January 2025 Options Trading For Arcellx (ACLX) - Nasdaq

Arcellx, Inc. (NASDAQ:ACLX) Short Interest Down 5.8% in October - MarketBeat

Arcellx, Inc. (NASDAQ:ACLX) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Arcellx (NASDAQ:ACLX) Shares Down 6.4%What's Next? - MarketBeat

Perceptive Advisors LLC Adjusts Position in Arcellx Inc - GuruFocus.com

Paradigm Biocapital Advisors LP Acquires Significant Stake in Ar - GuruFocus.com

arcellx director Kavita Patel sells $159,495 in stock - Investing.com

Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice - Yahoo Finance

FMR LLC Adjusts Stake in Arcellx Inc - GuruFocus.com

arcellx CFO Michelle Gilson sells $1.24 million in stock By Investing.com - Investing.com South Africa

Arcellx director Kavita Patel sells $5.97 million in stock - Investing.com

arcellx CFO Michelle Gilson sells $1.24 million in stock - Investing.com

Arcellx director Kavita Patel sells $5.97 million in stock By Investing.com - Investing.com UK

Truist reaffirms Buy on Arcellx, cites long cash runway and positive CAR-T safety profile - Investing.com

US Bancorp DE Acquires 2,851 Shares of Arcellx, Inc. (NASDAQ:ACLX) - Defense World

Arcellx, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights - Defense World

Objective long/short (ACLX) Report - Stock Traders Daily

Piper Sandler Forecasts Strong Price Appreciation for Arcellx (NASDAQ:ACLX) Stock - Defense World

Arcellx Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

HC Wainwright Has Optimistic Outlook of Arcellx Q3 Earnings - Defense World

Analyst Expectations For Arcellx's Future - Benzinga

Arcellx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Arcellx (NASDAQ:ACLX) Hits New 1-Year High on Analyst Upgrade - Defense World

Arcellx earnings missed by $0.14, revenue fell short of estimates - Investing.com UK

HC Wainwright Estimates Arcellx's Q3 Earnings (NASDAQ:ACLX) - MarketBeat

HC Wainwright Boosts Arcellx (NASDAQ:ACLX) Price Target to $95.00 - Defense World

Needham & Company LLC Reiterates Buy Rating for Arcellx (NASDAQ:ACLX) - Defense World

Morgan Stanley Forecasts Strong Price Appreciation for Arcellx (NASDAQ:ACLX) Stock - Defense World

Bank of America Raises Arcellx (NASDAQ:ACLX) Price Target to $100.00 - Defense World

Arcellx : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q) - Marketscreener.com

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights - BioSpace

Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar? - MSN

Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance

Arcellx stock soars to all-time high of $97.61 amid robust growth - Investing.com India

Arcellx (NASDAQ:ACLX) Hits New 52-Week High on Analyst Upgrade - MarketBeat

Arcellx (ACLX) Releases Clinical Data from Phase 1 and iMMagine-1 Studies for Multiple Myeloma Patients On November 5, 2024, Arcellx, Inc. (NASDAQ: ACLX) made public an abstract containing fresh clinical data from its Phase 1 and iMMagine-1 - Defense World

Arcellx price target raised to $106 from $81 at Morgan Stanley - Yahoo Finance

How Arcellx (ACLX) Stock Stands Out in a Strong Industry - MSN

ASH ’24: Arcellx Mounts Strong Challenge To Myeloma CAR-T Rival Carvykti - News & Insights

Arcellx stock target increased, rating held on positive trial data - Investing.com

Arcellx (NASDAQ:ACLX) Receives Buy Rating from Needham & Company LLC - MarketBeat

Arcellx (NASDAQ:ACLX) Price Target Raised to $100.00 - MarketBeat

Arcellx (NASDAQ:ACLX) Price Target Raised to $106.00 at Morgan Stanley - MarketBeat

Robert W. Baird Issues Positive Forecast for Arcellx (NASDAQ:ACLX) Stock Price - MarketBeat

HC Wainwright Increases Arcellx (NASDAQ:ACLX) Price Target to $95.00 - MarketBeat

Gilead, Arcellx Tout Best-in-Class Potential for CAR T Therapy in Multiple Myeloma - BioSpace

Arcellx shares target upgraded, maintains buy on positive trial data By Investing.com - Investing.com South Africa

Arcellx stock target increased, rating held on positive trial data By Investing.com - Investing.com UK

Navigating 7 Analyst Ratings For Arcellx - Benzinga

Arcellx to present positive data on multiple myeloma treatments - PharmaTimes

BofA raises Arcellx price target to $100 on positive data By Investing.com - Investing.com South Africa

INCY

$71.72

1.89%

SMMT

$19.00

3.15%

MRNA

$41.11

7.48%

UTHR

$372.89

1.51%

BGNE

$190.51

2.08%

BNTX

$113.13

4.53%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters